share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募資說明書
美股SEC公告 ·  05/16 12:45
Moomoo AI 已提取核心訊息
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated April 2, 2024, with details from its quarterly report filed with the SEC. The supplement pertains to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated information and should be read in conjunction with the original prospectus. Panbela Therapeutics has incurred significant losses since inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus and Quarterly Report. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving success in its development efforts and commercialization of its product candidates.
Panbela Therapeutics, Inc. filed a prospectus supplement on May 15, 2024, to update and supplement information in its previous prospectus dated April 2, 2024, with details from its quarterly report filed with the SEC. The supplement pertains to the issuance of 8,750,000 shares of common stock underlying previously issued Class E and Class F common stock purchase warrants. The shares were initially registered on a registration statement and are quoted on the OTCQB under the symbol 'PBLA.' The last reported sales price of the common stock was $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated information and should be read in conjunction with the original prospectus. Panbela Therapeutics has incurred significant losses since inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus and Quarterly Report. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving success in its development efforts and commercialization of its product candidates.
Panbela Therapeutics, Inc.於2024年5月15日提交了招股說明書補充文件，以更新和補充其先前於2024年4月2日發佈的招股說明書中的信息，詳細信息來自其向美國證券交易委員會提交的季度報告。該補充文件涉及發行8,750,000股普通股，標的先前發行的E類和F類普通股購買權證。這些股票最初是在註冊聲明上註冊的，並在OTCQB上市，股票代碼爲 “PBLA”。截至2024年5月14日，上次公佈的普通股銷售價格爲每股0.4408美元。該補編包括所附的季度報告，提供了最新的信息，應與原始招股說明書一起閱讀。正如招股說明書和季度報告的 “風險因素” 部分所詳述的那樣，Panbela Therapeutics自成立以來就蒙受了重大損失，並且繼續面臨高度的風險。該公司能否繼續經營取決於能否獲得額外的融資，以及在開發工作和候選產品的商業化方面取得成功。
Panbela Therapeutics, Inc.於2024年5月15日提交了招股說明書補充文件，以更新和補充其先前於2024年4月2日發佈的招股說明書中的信息，詳細信息來自其向美國證券交易委員會提交的季度報告。該補充文件涉及發行8,750,000股普通股，標的先前發行的E類和F類普通股購買權證。這些股票最初是在註冊聲明上註冊的，並在OTCQB上市，股票代碼爲 “PBLA”。截至2024年5月14日，上次公佈的普通股銷售價格爲每股0.4408美元。該補編包括所附的季度報告，提供了最新的信息，應與原始招股說明書一起閱讀。正如招股說明書和季度報告的 “風險因素” 部分所詳述的那樣，Panbela Therapeutics自成立以來就蒙受了重大損失，並且繼續面臨高度的風險。該公司能否繼續經營取決於能否獲得額外的融資，以及在開發工作和候選產品的商業化方面取得成功。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息